Cost-Effectiveness: Cholinesterase inhibitors and memantine in vascular dementia

Canadian Journal of Neurological Sciences

Volumn 36, Issue 6, 2009, Pages 735-739

  Wong, Camilla L ^a,e   Bansback, Nick ^b   Lee, Philip E ^c   Anis, Aslam H ^b,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR HEALTH EVALUATION AND OUTCOME SCIENCES   (Canada)

^c Division of Geriatric Medicine

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE;

AGING; ALZHEIMER DISEASE; ANOREXIA; ARTICLE; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; COGNITION; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; MULTIINFARCT DEMENTIA; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VOMITING;

EID: 70350303927     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100008350     Document Type: Article

References (20)

1. Ostbye T, Crosse E. Net economic costs of dementia in Canada. CMAJ. 1994;151:1457-1464
2. Health Canada. Economic burden of illness in Canada, 1998. Catalogue number: H21-136/1998E; 2002.
3. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54: 447-451 (Pubitemid 30078082)
4. Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE et al. A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22:265-274
5. Swartz RH, Sahlas DJ, Black SE. Strategic involvement of cholinergic pathways and executive dysfunction: Does location of white matter signal hyperintensities matter? J Stroke Cerebrovasc Dis. 2003;12:29-36.
6. Auchus AP, Brashear HR, Salloway S, Korczyn AD, De Deyn PP, Gassmann-Mayer C, et al. Galantamine treatment of vascular dementia: A randomized trial. Neurology. 2007;69:448-458
7. Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke. 2003;34:2323-2330
8. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's's disease combined with cerebrovascular disease: A randomised trial. Lancet. 2002;359: 1283-1290 (Pubitemid 34310633)
9. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: A randomized, placebocontrolled study. Neurology. 2003;61:479-486
10. Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res. 1998;116:331-347
11. Mobius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alzheimer Dis Assoc Disord. 1999;13 Suppl 3:S172-8.
12. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke. 2002;33:1834-1839
13. Wilcock G, Mobius HJ, Stoffler A; MMM 500 group. A doubleblind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002;17:297-305. (Pubitemid 35283717)
14. Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: A meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782-792
15. Bocti C, Black S, Frank C. Management of dementia with a cerebrovascular component. Alzheimers Dement. 2007;3: 398-403.
16. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology. 1993;43:250-260
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-III-R. 3rd ed. Washington, DC: American Psychiatric Association; 1987.
18. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.
19. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
20. Korczyn AD. Drugs for vascular dementia. Lancet Neurology. 2007;6:749-751